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Abstract: Thalidomide has shown efficacy in the treatment of advanced refractory multiple myeloma
even after autologous stem-cell transplantation [1] and has been evaluated alone or in combination in
the treatment of various solid and hematological malignancies [2–4]. Both antiangiogenic activity [5]
and the immunomodulatory properties of thalidomide are proposed mechanisms for its beneficial effects
[6]. Common side-effects during treatment with thalidomide are sedation, constipation, skin rash and
peripheral neuropathy. Less frequently bradycardia, hypotension and hypothyroidism have been described
[7]. However, life-threatening toxicity due to thalidomide has occurred as toxic epidermal necrolysis
[1], and in combination with steroids or anthracycline-based chemotherapy an increased incidence of
thromboembolic events has been observed [8].
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Severe hepatic toxicity due to 
thalidomide in relapsed multiple 
myeloma
Thalidomide has shown efficacy in the treatment of advanced
refractory multiple myeloma even after autologous stem-cell
transplantation [1] and has been evaluated alone or in com-
bination in the treatment of various solid and hematological
malignancies [2–4]. Both antiangiogenic activity [5] and the
immunomodulatory properties of thalidomide are proposed
mechanisms for its beneficial effects [6]. Common side-effects
during treatment with thalidomide are sedation, constipation,
skin rash and peripheral neuropathy. Less frequently brady-
cardia, hypotension and hypothyroidism have been described
[7]. However, life-threatening toxicity due to thalidomide has
occurred as toxic epidermal necrolysis [1], and in combination
with steroids or anthracycline-based chemotherapy an increased
incidence of thromboembolic events has been observed [8].
We report a 62-year-old female patient with refractory multiple
myeloma who developed severe liver toxicity during treatment
with thalidomide. The patient was diagnosed with multiple
myeloma (IgG κ) stage II A, in 1993. She did not respond to
either the initial chemotherapy with melphalan and prednisone in
1995 or the subsequent five cycles of chemotherapy with vin-
cristine, doxorubicin and dexamethasone 1 year later. An attempt
to collect autologous peripheral stem cells was unsuccessful. In
1997, she was treated with six cycles of vinorelbine and dexa-
methasone and had a minor response with regard to the para-
protein excretion.
Owing to progressive disease with painful osteolytic lesions
and renal impairment, treatment with thalidomide (200 mg/day)
and dexamethasone (40 mg/day for 4 days twice per month) was
initiated in October 2001. Again, a minor response could be docu-
mented after 2 months of treatment by the decline in the para-
protein. Three months later, pulmonary embolism occurred and
the patient received oral anticoagulation with phenprocoumon;
however, treatment with thalidomide and dexamethasone was
not discontinued. Seven months after initiation of thalidomide,
the patient rapidly developed malaise, progressive weakness and
peripheral neuropathy. She presented with flapping tremor and
elevated transaminases (50 × upper normal value) indicating
severe liver damage; bilirubin, alkaline phosphatase, calcium and
potassion were within their normal ranges. Serology revealed no
acute infection with hepatitis virus A, B or C. She had impaired
renal function (creatinine 250 µmol/l), anemia (hemoglobin
9.0 g/dl) and hypoalbuminemia (28 g/l). While on oral anticoagu-
lation, prothrombin time was decreased to 14% (international
normalized ratio 4.0). There were no clinical signs of cardiac
failure: the ejection fraction according to cardiac ultrasound was
67%.
The patient had been under medication with trimipramine,
transdermal fentanyl and co-trimoxazole (double-strength tablets
three times per week) for >4 years and with monthly pamidronate
infusions for >6 years, without any significant clinical or labora-
tory side-effects. We suspected toxicity due to thalidomide and
stopped the drug; all other medication remained unchanged. Of
note, aspartate aminotransferase declined to normal values 6 days
after thalidomide withdrawal (Figure 1, arrow) and alanine amino-
transferase after 7 days. Since the elevation of transaminases
resolved rapidly, a liver biopsy was not performed. This prompt
resolution after the cessation of thalidomide strongly suggests
that thalidomide was the causative agent of the hepatic toxicity.
So far, thalidomide-associated hepatitis, which had resolved
1 week after withdrawal of thalidomide and dexamethasone, has
only been described in a female with chronic asymptomatic
hepatitis C infection, who was treated for plasma cell leukemia
[9].
With the increasing use of thalidomide in various indications,
several previously rare and possibly unrecognized side-effects
may emerge. Based on our findings we recommend regulary
monitoring of liver enzymes during thalidomide treatment.
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Figure 1. Biochemistry results before and after thalidomide cessation 
(arrow).
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